Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/intubation -125% Improvement Relative Risk c19hcq.org Saib et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? PSM prospective study of 104 patients in France Higher death/intubation with HCQ (not stat. sig., p=0.23) Saib et al., PLOS ONE, doi:10.1371/journal.pone.0252388 Favors HCQ Favors control
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study
Saib et al., PLOS ONE, doi:10.1371/journal.pone.0252388
Saib et al., Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A.., PLOS ONE, doi:10.1371/journal.pone.0252388
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
203 hospitalized patients in France, not showing significant differences with treatment. Confounding by indication is likely. Authors do not discuss confounding. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
risk of death/intubation, 125.0% higher, RR 2.25, p = 0.23, treatment 9 of 52 (17.3%), control 4 of 52 (7.7%), PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Saib et al., 9 Jun 2021, prospective, propensity score matching, France, peer-reviewed, 9 authors, average treatment delay 7.2 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: PLOS ONE RESEARCH ARTICLE Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study Anis Saib1, Walid Amara1, Pascal Wang ID2, Simon Cattan1, Azeddine Dellal3, Kais Regaieg4, Stephane Nahon5, Olivier Nallet1, Lee S. Nguyen ID6* a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 1 Cardiology Department, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, 2 Pneumology Department, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, 3 Rheumatology Department, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, 4 Intensive Care Medicine Department, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, 5 Gastroenterology Department, Groupe Hospitalier Intercommunal Le RaincyMontfermeil, Montfermeil, France, 6 Research & Innovation Department (RICAP), CMC Ambroise Paré, Neuilly-sur-Seine, France * nguyen.lee@icloud.com Abstract Background OPEN ACCESS Citation: Saib A, Amara W, Wang P, Cattan S, Dellal A, Regaieg K, et al. (2021) Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. PLoS ONE 16(6): e0252388. https://doi.org/10.1371/journal.pone.0252388 Editor: Andrea Cortegiani, University of Palermo, ITALY Received: January 14, 2021 Accepted: May 17, 2021 Published: June 9, 2021 Copyright: © 2021 Saib et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files. Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19). In this retrospective study, we assessed the clinical effects of HCQ/AZI, with a 28-days follow-up. Methods In a registry-study which included patients hospitalized for COVID-19 between March 15 and April 2, 2020, we compared patients who received HCQ/AZI to those who did not, regarding a composite outcome of mortality and mechanical ventilation with a 28-days follow-up. QT was monitored for patients treated with HCQ/AZI. Were excluded patients in intensive care units, palliative care and ventilated within 24 hours of admission. Three analyses were performed to adjust for selection bias: propensity score matching, multivariable survival, and inverse probability score weighting (IPSW) analyses. Results Overall, 203 patients were included: 60 patients treated by HCQ/AZI and 143 control patients. During the 28-days follow-up, 32 (16.3%) patients presented the primary outcome and 23 (12.3%) patients died. Propensity-score matching identified 52 unique pairs of patients with similar characteristics. In the matched cohort (n = 104), HCQ/AZI was not associated with the primary composite outcome (log-rank p-value = 0.16). In the overall cohort (n = 203), survival and IPSW analyses also found no benefit from HCQ/AZI. In the HCQ/AZI group, 11 (18.3%) patients prolonged QT interval duration, requiring treatment cessation. PLOS ONE | https://doi.org/10.1371/journal.pone.0252388 June 9,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit